VANI

Business Context and Reporting Period

Company: Second Sight Medical Products, Inc. (Note: Input metadata referenced "Vivani Medical," but the filing text identifies the registrant as Second Sight Medical Products, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2014
Business Overview: Second Sight is a medical device company developing implantable visual prosthetics. Its primary commercial product is the Argus II System, the only retinal prosthesis approved by the FDA and CE-marked in Europe to restore functional vision to patients with retinitis pigmentosa (RP). The company completed its Initial Public Offering (IPO) in November 2014.

Key Financial Metrics

Note: The 2014 Net Loss includes a non-cash write-off of $6,954,610 related to the conversion of convertible promissory notes upon the IPO.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 117% to $3.4 million, driven by 29 implants in 2014 (vs. 22 in 2013) and the introduction of sales in the U.S. and Canada. The U.S. accounted for 47% of revenue in 2014.
• Gross Margin Improvement: The company achieved a positive gross margin in Q3 and Q4 2014 for the first time, though the full-year result remained a slight loss due to inventory write-downs and manufacturing inefficiencies earlier in the year.
• Expense Increases: Selling and marketing expenses doubled (107%) to $6.8 million to support U.S. commercialization. Research and development expenses rose 55% to $5.0 million.
• Liquidity Transformation: Following the November 2014 IPO, the company raised approximately $34.2 million in net proceeds. This converted the company from a deficit equity position in 2013 to positive equity of $34.6 million in 2014. All outstanding convertible promissory notes were converted to common stock.

Guidance, Outlook, and Risks

• Product Pipeline: The company is conducting a pilot study for the Argus II System in patients with Age-Related Macular Degeneration (AMD), with implants planned for the first half of 2015. It is also developing the Orion I visual cortical prosthesis to treat a broader range of blindness, with pre-clinical development expected to complete by mid-2016.
• Commercialization: Management plans to use IPO proceeds to expand sales and marketing in the U.S. and Europe. Reimbursement remains a critical hurdle; while Medicare transitional pass-through payments are secured, universal coverage is not yet established.
• Capital Needs: Management believes current cash resources are sufficient to fund operations for approximately 18 to 24 months. Additional financing may be required thereafter.
• Key Risks:
  • Reimbursement: Failure to obtain adequate reimbursement from government and private payers could materially harm revenue.
  • Manufacturing: The company has limited large-scale manufacturing experience and currently faces low yields, which impacts cost of sales.
  • Intellectual Property: Ongoing patent oppositions in the European Patent Office by competitor Pixium Vision could impact future competitive positioning.
  • Profitability: The company has a history of operating losses and may continue to incur losses for the foreseeable future.

Investor Verification Checklist

• Reimbursement Status: Verify the current status of Medicare coverage across all Administrative Contractors (MACs) and private payer contracts, as this is the primary driver of U.S. sales.
• Manufacturing Yields: Assess progress in improving manufacturing yields and reducing the cost of sales to achieve sustainable gross margins.
• AMD Trial Progress: Monitor the recruitment and implantation timeline for the Age-Related Macular Degeneration (AMD) pilot study, as this represents a significant market expansion opportunity.
• Patent Litigation: Review the status of the nine European patent oppositions filed by Pixium Vision to understand potential impacts on the IP portfolio.
• Cash Burn Rate: Confirm the runway of the $34.2 million IPO proceeds against the projected 18-24 month operational timeline.